Caplin Point Laboratories Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/nearzxyc6upwx83vrflruu1d.pdf

Key Takeaways


US Business: From Cash Burn to Compounder

Vivek Partheeban: "We are not seeing a dearth of orders. In fact, we have an order book that is full for another six months almost."

LATAM: Tender Lumpiness and Structural Build-Out

C.C. Paarthipan: "When you develop the credence for your business over a period of time and you establish the KPIs through video SOPs, then it is simply going above and beyond. That is the deliberate growth."

Capacity Expansion: The Unlocking Catalyst


Balance Sheet & Cash Flow Quality

C.C. Paarthipan: "During volatile periods, the cash becomes the strategic oxygen."

Margin Structure & Drags

Vivek Partheeban: "Despite all these drags on our bottom line, we are still looking at 27%, 28% PAT and 38%, 39% EBITDA, which in my opinion, at least from whatever I have seen in our size segment, nobody else has these numbers."

Inorganic & Strategic Optionality

C.C. Paarthipan: "Going for the sake of acquisition, I would not advise us to go for actually acquisition without going for a meaningful acquisition. That will be a vanity."

Guidance & Commitments

CommitmentSpecificsTimeline
US own-label revenueDouble from ~INR 100 cr to ~INR 200 crNext year (FY27)
Overall growth expectation25% to 30%Next year (FY27)
El Salvador tender receivable collectionFull collection of amount shipped in Feb/MarchEnd of Q2 FY27
Mexico facility construction startBuilding to beginQ3 or Q4 FY27
Mexico sales target~$4 mnComing two quarters
Chile product supply135 products worth ~$10 mnNext 18 months
Residual capex spendINR 510 crNext 18–24 months
Injectable line count17 lines for US and regulated marketsNext 2–3 years
LATAM numbers recoveryReturn to previous growth levels18 months and beyond
Receivable days rangeComfortable at 100–120 days, possibly up to 130 daysGoing forward

Key Metrics

MetricQ4 FY26
Revenue (FY26)₹2,300 cr, doubled from ₹1,085 cr in FY25-26
Revenue growth (FY26)13%, profit growth of 20% ahead of revenue growth
EBITDA, PBT, PAT growth (FY26)2.5x increase over the last five years
Net worth₹3,331 cr, expanded by ₹745 cr during the year, 26% growth
Cash reserves₹1,471 cr, free cash reserves tripled from ₹470 cr
Liquid assets₹2,726 cr, tripled from ₹928 cr
Operating cash flow (FY26)₹523 cr, representing 80% cash conversion of PAT
R&D spend (FY26)~₹100 cr, crossed ₹100 cr for the first time, almost 5% of turnover
Capex incurred (FY26)₹248 cr, peak rate for the year
Receivable days136 days, 11 days attributable to FCTR; would have been 125 days otherwise
US business revenue growth~20%
Caplin Steriles EBITDA margin (Q4)33%
Caplin Steriles EBITDA margin (FY26)30%, up from 27.9% in FY25
US own-label revenue (FY26)~₹100 cr, in first full year of operations
US ANDA tally60 ANDAs as of May 2026, 10 approvals and 15 acquisitions in FY26
LATAM ex-US revenue (Q4)₹470 cr, up from ₹432 cr in Q3, driven by El Salvador tender
Mexico expected sales (next two quarters)~$4 million
Chile product registrations135 registrations received, ~40 more submitted
Central America pharmacy shelf space41%, expected to reach 57% with liquid registrations
Forex translation reserve movement₹141 cr, added directly to reserves
Fixed assets turnover ratio3.91x
Inventory sales potential (market and WIP)~₹900 cr
Residual capex to be spent₹510 cr, over next 18–24 months